Abbott Vascular

3200 Lakeside Dr.

Santa Clara

95054

USA

(408) 845-3000

http://www.abbottvascular.com

Product Categories

Embolic Protection Devices, Stents, Stents Drug Eluting, Vascular Closure Devices, Stents Carotid, Stents Peripheral, Stents Bare Metal

Related Content

Videos | Structural Heart

VIDEO: Abbott Structural Heart Technology Advances in 2021

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

September 20, 2021

News | Left Atrial Appendage (LAA) Occluders

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

August 31, 2021

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

Abbott's new interventional imaging platform powered by Ultreon 1.0 Software is a first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Optical Coherence Tomography (OCT)

FDA Clears Abbott OCT Imaging Enhanced With Artificial Intelligence

August 5, 2021 — The U.S. Food and Drug Administration (FDA) has cleared clearance Abbott's latest optical coherence ...

August 05, 2021

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.

Feature | Ventricular Assist Devices (VAD)| By Dave Fornell, Editor

Medtronic Ends Sales of HVAD Ventricular Assist System

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular ...

July 08, 2021

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

News | Stents

FDA Clears Xience Stent for One Month DAPT in High Risk Bleeding Patients

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...

June 30, 2021

News | EP Lab

Abbott Recalls Assurity and Endurity Pacemakers

May 14, 2021 — Abbott is recalling a subset of Assurity and Endurity pacemakers built using specific manufacturing ...

May 14, 2021

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

News | Cath Lab

Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

May 12, 2021

The new generation Abbott TriClip G4 device has gained European and Canadian approvals for transcatheter tricuspid valve repair (TTVR).

News | Structural Heart

Abbott Receives CE Mark and Canadian Approval for Next-Generation TriClip Tricuspid Valve Repair Device

April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for ...

April 08, 2021

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2]

News | Stents

Abbott’s Xience Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy for High Bleeding Risk Patients

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

April 06, 2021